LXEO · Lexeo Therapeutics
AI read · Good for LXEO
The AI's read
The early findings point to fewer abnormal heart rhythms in people receiving LX2020. The FDA is open to using NSVT as a main measure for possible faster approval. The treatment is still being tested, and Lexeo plans to finalize its pivotal study design in 2027. Cash is expected to cover operations into 2028, though quarterly research spending shows the work uses cash.